Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Acronet, ICON to Collaborate in CRO Business
May 2, 2011
- OTC Ketotifen to be Reclassified as Class 2
May 2, 2011
- FPMAJ Proposes Rotating Production for Some Makers this Summer
May 2, 2011
- “Generally Favorable”Outlook for Dispensing Pharmacies in FY2011: Analyst
May 2, 2011
- What Is on the Mind of Japan's Pharmaceutical Executives?
May 2, 2011
- Quake-hit Plant to Return to Full Operation by Sept.: Chugai
May 2, 2011
- 33 Drugs Approved Including LIXIANA
May 2, 2011
- Bayer Starts Multinational PIII Trial for VEGF Trap-Eye in DME
May 2, 2011
- Production of Pravastatin Drug Substance to Resume in Sept.: Daiichi Sankyo
May 2, 2011
- Eisai's Halaven for Inoperable Breast Cancer
May 2, 2011
- Lixisenatide Reduces HbA1c in Combination with SU or SU + Metformin
May 2, 2011
- No Problem with Radioactive Contamination of Drugs: FPMAJ
May 2, 2011
- Daiichi Sankyo's Edoxaban for VTE Prevention
May 2, 2011
- Toyobo, Kyowa Medex to Comarket GENECUBE
May 2, 2011
- DSP's 200 Pharmacist Employees to Volunteer in Disaster Area
May 2, 2011
- Mochida's Lexapro for Depression
May 2, 2011
- Drugs Provided Free of Charge to Be Reimbursed in Disaster Areas
May 2, 2011
- Astellas Pharma Announces Changes in Leadership
May 2, 2011
- Japan's 1st Transdermal Patch for AD Rivastigmine: Novartis, Ono
May 2, 2011
- Lilly to Expand Japan Business via Alliances with Subsidiaries in Other Asian Countries
May 2, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…